# Thevetia neriifolia (Thevetia neriifolia Juss. ex A. DC.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/thevetia-neriifolia-thevetia-neriifolia-juss-ex-a-dc
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Exile tree, Yellow Oleander, Thevetia neriifolia Juss. ex A. DC., Yellow Oleander (Thevetia neriifolia), Lucky Nut, Thevetia peruviana, Cascabela thevetia, Be-still tree

## Overview

Thevetia neriifolia contains potent cardiac glycosides (neriifolin, thevetin, peruvoside) alongside phenolic acids (rosmarinic acid at 13.48 mg/g), flavonoids (rutin at 7.33 mg/g), and fatty acids that collectively disrupt bacterial cell membrane integrity and inhibit insect physiology. In vitro studies demonstrate bactericidal activity against Pseudomonas aeruginosa, Salmonella typhi, and Escherichia coli at minimum bactericidal concentrations of 50 mg/ml for seed oil, while leaf extracts inhibit multiple bacterial pathogens across concentrations of 50–200 mg/ml.

## Health Benefits

- **Antibacterial Activity**: Leaf extracts and seed oil exhibit broad-spectrum antibacterial effects against gram-negative pathogens including E. coli, Salmonella typhi, and Pseudomonas aeruginosa; transmission electron microscopy confirms that the latex induces structural disruption of bacterial cell walls and membranes.
- **Antifungal Properties**: Hexadecanoic acid (palmitic acid), identified as a major GC-MS peak in leaf extracts, demonstrates documented antifungal activity and has historically informed the plant's traditional use against dermatophytic infections such as ringworm in Egyptian folk medicine.
- **Wound Healing Promotion**: In rodent excision wound models, topical application of T. neriifolia extracts achieved complete wound closure by day 14 with elevated hydroxyproline content (65.73 ± 3.2 mg/g in treated tissue), suggesting [collagen synthesis](/ingredients/condition/skin-health) stimulation mediated by phenolic antioxidants.
- **Antioxidant Defense Upregulation**: Phenolic compounds including rosmarinic acid and rutin upregulate endogenous antioxidant enzymes—glutathione peroxidase, catalase, and superoxide dismutase—while concurrently reducing [oxidative stress](/ingredients/condition/antioxidant) biomarkers in preclinical models.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Effects**: 9,12-Octadecadienoic acid (linoleic acid), present in leaf volatile fractions, exerts [hepatoprotective](/ingredients/condition/detox) and anti-inflammatory activity by modulating eicosanoid biosynthetic pathways, reducing pro-inflammatory mediator production in vitro.
- **Insecticidal and Pesticidal Activity**: The cardiac glycoside fraction and saponin content (2.920 ± 0.010 mg/g) contribute to documented insecticidal properties exploited in Egyptian folk remedies, with these compounds disrupting Na⁺/K⁺-ATPase function in arthropod nervous tissue.
- **Potential Antitumor Activity**: Traditional use of the plant against external tumors aligns with preliminary in vitro data suggesting cytotoxic properties attributable to the cardiac glycoside constituents, which are known to induce apoptosis in cancer cell lines at sub-toxic concentrations in related Apocynaceae species.

## Mechanism of Action

The cardiac glycosides of T. neriifolia—principally neriifolin, thevetin A and B, and peruvoside—inhibit the plasma membrane Na⁺/K⁺-ATPase enzyme, elevating intracellular sodium and secondarily increasing intracellular calcium via the Na⁺/Ca²⁺ exchanger, which underlies both the plant's cardiotonic pharmacology and its cytotoxic and insecticidal effects. Rosmarinic acid and rutin, the dominant phenolic acid and flavonoid respectively, scavenge [reactive oxygen species](/ingredients/condition/antioxidant) directly and activate the Nrf2/ARE transcriptional pathway, inducing expression of [glutathione](/ingredients/condition/detox) S-transferase, catalase, and superoxide dismutase. Hexadecanoic acid and squalene in the leaf volatile fraction integrate into bacterial phospholipid bilayers, increasing membrane permeability and dissipating the proton motive force necessary for [ATP synthesis](/ingredients/condition/energy) and active transport, explaining the observed ultrastructural cell wall and membrane damage in S. aureus and P. aeruginosa under electron microscopy. Saponins further synergize [antimicrobial](/ingredients/condition/immune-support) action through membrane cholesterol complexation, creating transient pores that amplify leakage of cytoplasmic contents from microbial and fungal cells.

## Clinical Summary

No human clinical trials have been conducted on Thevetia neriifolia or its extracts for any indication, representing a critical gap in the evidence base. Existing preclinical data are derived from in vitro [antimicrobial](/ingredients/condition/immune-support) assays and a small number of animal wound-healing experiments, none of which report effect sizes derived from adequately powered, controlled study designs with published sample sizes. The documented toxicity of the plant's cardiac glycoside fraction—a class of compounds with narrow therapeutic indices even in well-studied congeners such as digoxin—substantially complicates any pathway toward human clinical investigation. Confidence in translating existing laboratory findings to clinical recommendations is therefore very low, and the ingredient should be regarded as a research-stage botanical with potential mechanistic interest rather than a validated therapeutic agent.

## Nutritional Profile

Thevetia neriifolia is not consumed as a food ingredient and has no relevant macronutrient profile for nutritional purposes. The seed contains measurable phytochemical classes including alkaloids (0.062 ± 0.001 mg/g), flavonoids (3.123 ± 0.005 mg/g), glycosides (0.163 ± 0.010 mg/g), phytates (4.530 ± 0.01 mg/g), saponins (2.920 ± 0.010 mg/g), and tannins (3.140 ± 0.014 mg/g). Leaf polar fractions contain rutin at 7.33 mg/g and rosmarinic acid at 13.48 mg/g as quantified by HPLC, while GC-MS analysis of volatile fractions identifies farnesol (13.48% peak area), squalene (7.69% peak area), hexadecanoic acid, and 9,12-octadecadienoic acid as major constituents. Bioavailability of any constituent following oral ingestion is entirely unstudied, and the co-presence of high-phytate levels (4.530 mg/g) would be expected to reduce mineral bioavailability if the plant were consumed, which is not recommended given its toxicity profile.

## Dosage & Preparation

- **Traditional Topical Latex Application**: Undiluted or diluted fresh latex has been applied externally to infected wounds, skin lesions, and ringworm-affected areas in Egyptian folk practice; no standardized concentration or dose is established.
- **Leaf Extract (In Vitro Reference Concentration)**: Inhibitory concentrations in laboratory studies range from 50 to 200 mg/ml; these concentrations are not translatable to human supplemental doses and are provided for research context only.
- **Seed Oil (In Vitro Reference)**: Minimum bactericidal concentration against gram-negative bacteria established at 50 mg/ml in vitro; no safe human topical or oral dose has been defined.
- **Insecticidal Preparations**: Traditional use involves plant material preparations applied to grain stores or infested areas; exact preparation ratios are undocumented in peer-reviewed sources.
- **CRITICAL NOTE**: No standardized supplement form, commercial formulation, or evidence-based dosing regimen exists for internal use. Given confirmed cardiac glycoside toxicity, oral ingestion of any plant part outside of medically supervised settings is contraindicated. Consultation with a qualified healthcare provider is mandatory before any therapeutic application.

## Safety & Drug Interactions

Thevetia neriifolia is classified as a highly toxic plant; all parts—particularly the seeds, latex, and bark—contain cardiac glycosides (neriifolin, thevetin A/B, peruvoside) that inhibit Na⁺/K⁺-ATPase and can cause life-threatening arrhythmias, heart block, severe bradycardia, nausea, vomiting, and death following ingestion, with documented fatalities in humans reported in the toxicological literature. Persons taking cardiac glycoside medications (digoxin, digitoxin), antiarrhythmic agents, or drugs that alter potassium homeostasis (loop diuretics, potassium-sparing diuretics, ACE inhibitors) face a particularly severe additive risk of glycoside toxicity and must avoid any exposure. The plant is absolutely contraindicated during pregnancy and lactation due to potential abortifacient properties documented in traditional sources and the systemic toxicity risk to the fetus and infant. No maximum safe supplemental dose has been established because no dose is considered safe for internal consumption; topical use should also be approached with extreme caution due to documented dermal irritation from latex exposure and potential transdermal absorption of glycoside fractions.

## Scientific Research

Available evidence for T. neriifolia is confined entirely to in vitro studies and limited rodent model experiments; no randomized controlled trials in humans have been published as of current literature, making the evidence base preliminary at best. In vitro antibacterial studies have consistently demonstrated inhibitory activity at concentrations of 50–200 mg/ml for leaf extracts and 50 mg/ml minimum bactericidal concentration for seed oil against gram-negative pathogens, though these concentrations far exceed what is typically achievable in systemic human plasma. One rodent excision wound model reported complete healing by day 14 with quantified hydroxyproline improvement (65.73 ± 3.2 mg/g), representing the most rigorous preclinical outcome data available, yet sample sizes and full methodology are not comprehensively reported in accessible literature. The phytochemical profiling studies (GC-MS, HPLC quantification of rutin and rosmarinic acid) provide robust compositional data but do not establish pharmacokinetic or bioavailability parameters necessary for translational dosing in humans.

## Historical & Cultural Context

In Egyptian and broader Middle Eastern folk medicine, Thevetia neriifolia has been employed primarily as an externally applied remedy for bacterial skin infections, fungal conditions such as ringworm, and as an insecticidal agent to protect grain stores and living spaces, reflecting its recognition as a plant of both medicinal and agricultural utility. The plant's common Arabic designations and its presence in the traditional pharmacopeias of Egypt and Sudan align with its historical use alongside other toxic medicinal plants whose therapeutic applications were empirically narrowed to topical or fumigant routes to minimize systemic exposure. In South and Southeast Asia, where the plant has also naturalized, parallel traditions document use of bark decoctions and seed-derived preparations for treating fevers, skin parasites, and as abortifacients, reflecting a broad ethnopharmacological recognition of its potent bioactivity tempered by awareness of its danger. The plant's ornamental spread—facilitated by its bright yellow trumpet-shaped flowers—has contributed to widespread folk knowledge of its toxicity, with historical records from colonial-era India documenting cases of deliberate and accidental poisoning attributed to seed ingestion.

## Synergistic Combinations

No evidence-based synergistic ingredient combinations have been established for Thevetia neriifolia in peer-reviewed literature, reflecting the absence of clinical pharmacological investigation. Mechanistically, the combination of rosmarinic acid and rutin within the plant's own phytochemical matrix may represent an intra-ingredient synergy whereby phenolic [antioxidant](/ingredients/condition/antioxidant)s protect glycoside stability and amplify [anti-inflammatory](/ingredients/condition/inflammation) endpoints in topical wound-healing applications, consistent with patterns observed in other phenolic-glycoside co-extracts. Any deliberate formulation combining T. neriifolia extracts with other cardiac-active botanicals such as Nerium oleander, Digitalis species, or hawthorn (Crataegus spp.) would be pharmacologically hazardous due to additive Na⁺/K⁺-ATPase inhibition and is explicitly not recommended.

## Frequently Asked Questions

### Is Thevetia neriifolia safe to use medicinally?

Thevetia neriifolia is not safe for internal use; all plant parts contain cardiac glycosides including neriifolin and thevetin that inhibit Na⁺/K⁺-ATPase and have caused documented human fatalities through arrhythmia and heart block. External (topical) traditional use carries risk of latex-induced skin irritation and potential transdermal glycoside absorption, and should only be considered under qualified medical supervision. No safe supplemental dose has been established for any route of administration.

### What are the active compounds in Thevetia neriifolia?

The primary bioactive compounds are cardiac glycosides—neriifolin, acetyl neriifolin, thevetin A and B, peruvoside, theveside, and theviridoside—concentrated in seeds and flowers. The leaf polar fraction also contains rosmarinic acid (13.48 mg/g) and rutin (7.33 mg/g) as the dominant phenolic acid and flavonoid respectively, alongside volatile compounds such as farnesol (13.48% peak area) and squalene (7.69% peak area) with documented antimicrobial and antioxidant properties.

### What is Thevetia neriifolia used for in traditional Egyptian medicine?

In Egyptian folk medicine, Thevetia neriifolia has been applied topically to treat infected wounds, bacterial skin conditions, ringworm, and externally presenting tumors, and the plant material has been used as an insecticidal agent to protect grain stores and living spaces. These applications exploit the plant's documented antibacterial, antifungal, and insecticidal properties while limiting systemic glycoside exposure by avoiding oral ingestion. Preparation methods are informal and undocumented in standardized pharmacopeial records.

### Does Thevetia neriifolia have any proven antibacterial activity?

In vitro studies confirm antibacterial activity: seed oil reaches minimum bactericidal concentrations of 50 mg/ml against Pseudomonas aeruginosa, Salmonella typhi, and Escherichia coli, while leaf extracts inhibit multiple bacterial pathogens at concentrations of 50–200 mg/ml. Transmission electron microscopy has shown that the plant's latex causes structural disruption of bacterial cell walls and membranes in S. aureus and P. aeruginosa. However, no human clinical trials exist, and the in vitro concentrations are far higher than what is safely achievable in humans.

### Can Thevetia neriifolia interact with heart medications?

Yes—Thevetia neriifolia poses a severe interaction risk with cardiac glycoside medications (digoxin, digitoxin) because its own cardiac glycosides (neriifolin, thevetin, peruvoside) act on the same Na⁺/K⁺-ATPase target, creating additive toxicity risk with potentially fatal arrhythmias. Drugs that alter potassium balance—such as loop diuretics (furosemide), thiazides, or corticosteroids—further amplify cardiac glycoside toxicity by lowering serum potassium, increasing sensitivity of the cardiac conduction system. Any individual on cardiovascular medications must avoid all contact with and ingestion of this plant.

### What is the difference between Thevetia neriifolia leaf extract and seed oil for antibacterial use?

Both forms demonstrate antibacterial activity, but leaf extracts and seed oil may have different potencies and compound profiles. Seed oil is particularly rich in hexadecanoic acid (palmitic acid) and other fatty acids with documented antifungal properties, while leaf extracts provide a broader spectrum of phytochemicals. The choice between forms depends on the target pathogen and desired therapeutic application, as transmission electron microscopy studies show the latex induces structural disruption of bacterial membranes.

### Who should avoid using Thevetia neriifolia due to its cardiac glycoside content?

Individuals with pre-existing heart conditions, those taking cardiac medications, pregnant women, and children should avoid Thevetia neriifolia supplementation due to its potent cardiac glycosides that can affect heart function and rhythm. Elderly individuals with compromised kidney or liver function are also at higher risk for toxicity accumulation. Anyone with a history of arrhythmias or heart disease should consult a healthcare provider before considering this ingredient.

### What does current clinical research show about Thevetia neriifolia's antimicrobial efficacy compared to conventional antibiotics?

In vitro studies confirm broad-spectrum antibacterial activity against clinically relevant gram-negative pathogens including E. coli, Salmonella typhi, and Pseudomonas aeruginosa, with documented cell wall disruption mechanisms. However, clinical human trials are limited, and most evidence is derived from laboratory and traditional use data rather than controlled clinical studies. Additional research is needed to establish efficacy thresholds, optimal dosing, and how these effects translate to therapeutic outcomes in humans compared to standard antibiotic treatments.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*